Interview with Michaela Hrdličková, , Biogen Idec Czech Republic
Ms. Hrdličková, can you please begin by introducing yourself to our readers, and providing a brief overview…
Biogen Idec Czech Republic
Last updated: 13.02.2014
Address: Na Pankráci 1683/127 140 00 Praha 4,Czech Republic
Tel: +420 255 706 200
Web: http://www.biogenidec.cz/
Company description
Biogen Idec is a Fortune 500 company and global biotechnology leader that generates more than $5 billion in annual revenues. Our mission is to discover, develop and deliver innovative therapies for the treatment of neurodegenerative diseases, hemophilia, and immunology to patients worldwide through cutting-edge science and medicine. Our robust product pipeline is supported by one of the industry’s leading capacities for biologics manufacturing, featuring nearly 200,000 liters of bioreactor capacity.
We have more than 5,000 employees worldwide and a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including emerging markets such as Central and Eastern Europe, Brazil, China and India. We pursue our mission through a strategic combination of internal research and development and through partnerships, alliances, and acquisitions.
With an unshakeable commitment to our mission and values, we expect to build shareholder value by bringing meaningful therapies to patients with serious, unmet medical needs.
Biogen Idec has had an affiliate in the Czech market since 2006.
Products and services
Today, Biogen Idec is the oldest independent biotechnology company in the world. Patients worldwide benefit every day from its industry leading multiple sclerosis (MS) products. The company’s R&D efforts are focused on bringing new therapies to market for patients with neurodegenerative diseases, autoimmune disorders and hemophilia.
Interviews
Related
Roman Grunt – CEO, Quinta Analytica, Czech Republic
Roman Grunt, CEO of Quinta Analytica, gives us an overview of the activities of how the Czech firm has managed to…
Report / New Czech Republic Pharma Report April 2020 Out Now
PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Czech Republic is available for…
CEE / Medtech's Enduring Importance for Czech Healthcare
Key stakeholders within the Czech medtech industry highlight how medical devices can improve efficiency and quality…
Roman Samiec – General Manager, Thuasne Czech Republic
Roman Samiec, general manager of Thuasne Czech Republic, introduces the company as a key competitor in the medical…
Jiří Pavlíček – CEO, Aspironix & Chairman, CzechMed and Miroslav…
Miroslav Palát, president of CzechMed, the medical device association in the Czech Republic, and Jiří…
Pavla Nevolová – Country Head, EastHORN Czech Republic
Pavla Nevolová, country head of EastHORN in the Czech Republic, shares the historical roots of the now…
Clinical Trials / Finding the Niches in the Czech Republic
The Czech Republic boasts a solid clinical research infrastructure and a supportive regulatory environment, meaning…
Pharma Faces / Jiří Žák, Chairman of FARMAK, Czech Republic
In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a…
Company Spotlight / STADA Czech Republic
As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum,…
Roman Dusil – General Manager, Pierre Fabre Laboratories Czech Republic…
Roman Dusil, GM of Pierre Fabre Laboratories in the Czech Republic and Slovakia, shares how the Czech affiliate is…
Market Access / A New Era in the Czech Republic?
Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most…
Orphan Drugs / Building the Regulatory Framework in the Czech Republic
A cross-industry push for better and broader access to innovative treatments is underway in the Czech Republic.…
